Abdominal Radiology

, Volume 42, Issue 5, pp 1579–1582 | Cite as

Evaluation of infectious complications following percutaneous liver ablation in patients with bilioenteric anastomoses

  • B. T. WelchEmail author
  • J. J. Schmitz
  • T. D. Atwell
  • A. M. McGauvran
  • A. N. Kurup
  • M. R. Callstrom
  • G. D. Schmit



Prior bilioenteric anastomosis (BEA) has been associated with elevated risk of abscess formation after thermal ablation of hepatic tumors. We assessed the incidence of hepatic abscess after thermal ablation in a BEA cohort treated with extended antibiotic regimens following ablation.

Materials and methods

Retrospective review was performed to identify patients with BEA who underwent percutaneous hepatic thermal ablation between January 1, 2003–September 1, 2016. Fifteen patients with BEA underwent 18 percutaneous thermal ablation procedures. Patient and procedural characteristics were reviewed, as well as the antibiotic regiment utilized post ablation. Complications were characterized via standardized nomenclature [Common Terminology for Clinically Adverse Events (CTCAE) v4.03].


Fifteen patients with BEA underwent treatment of 49 liver lesions during 18 ablation sessions. Mean follow-up in these patients was 39 months (range 3–138 months). Two patients (11%) developed hepatic abscesses, both of which occurred within 45 days of the ablation procedure while the patients were still on extended prophylactic antibiotic therapy. No additional CTCAE clinically significant complications were observed.


Thermal ablation of hepatic tumors can be accomplished safely in patients with BEA. Long-term post-procedural antibiotics may mitigate the risk of hepatic abscess formation. Due to the high number of patients who are deemed surgically unresectable, patients with BEA may have limited alternate treatment modalities and percutaneous hepatic thermal ablative treatments warrant consideration.


Percutaneous ablation Hepatic neoplasms Tumor ablation 


Compliance with ethical standards


No funding was received for this study.

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Statement of informed consent was not applicable since the manuscript does not contain any patient data.


  1. 1.
    Clark ME, Smith RR (2014) Liver-directed therapies in metastatic colorectal cancer. J gastrointest oncol 5(5):374–387PubMedPubMedCentralGoogle Scholar
  2. 2.
    Foltz G (2014) Image-guided percutaneous ablation of hepatic malignancies. Semin Interv Radiol 31(2):180–186CrossRefGoogle Scholar
  3. 3.
    Murata S, Mine T, Sugihara F, et al. (2014) Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol 20(37):13453–13465CrossRefGoogle Scholar
  4. 4.
    Saied A, Katz SC, Espat NJ (2013) Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases. Hepatobiliary Surg Nutr 2(2):97–107PubMedPubMedCentralGoogle Scholar
  5. 5.
    Solbiati L, Ahmed M, Cova L, et al. (2012) Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 265(3):958–968CrossRefGoogle Scholar
  6. 6.
    Akahane M, Koga H, Kato N, et al. (2005) Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management. Radiographics 25(Suppl 1):S57–68CrossRefGoogle Scholar
  7. 7.
    de Baere T, Risse O, Kuoch V, et al. (2003) Adverse events during radiofrequency treatment of 582 hepatic tumors. Am J Roentgenol 181(3):695–700CrossRefGoogle Scholar
  8. 8.
    Hoffmann R, Rempp H, Schmidt D, et al. (2012) Prolonged antibiotic prophylaxis in patients with bilioenteric anastomosis undergoing percutaneous radiofrequency ablation. J Vasc Interv Radiol 23(4):545–551CrossRefGoogle Scholar
  9. 9.
    Fonseca AZ, Santin S, Gomes LG, et al. (2014) Complications of radiofrequency ablation of hepatic tumors: frequency and risk factors. World J Hepatol 6(3):107–113CrossRefGoogle Scholar
  10. 10.
    Choi D, Lim HK, Kim MJ, et al. (2005) Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. Am J Roentgenol 184(6):1860–1867CrossRefGoogle Scholar
  11. 11.
    Elias D, Di Pietroantonio D, Gachot B, et al. (2006) Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. Gastroenterol Clin Biol 30(6–7):823–827CrossRefGoogle Scholar
  12. 12.
    Livraghi T, olbiati L, Meloni MF, et al. (2003) Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 226(2):441–451CrossRefGoogle Scholar
  13. 13.
    Shibata T, Yamamoto Y, Yamamoto N, et al. (2003) Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol 14(12):1535–1542CrossRefGoogle Scholar
  14. 14.
    Iida H, Aihara T, Ikuta S, Yamanaka N (2014) Risk of abscess formation after liver tumor radiofrequency ablation: a review of 8 cases wtih a history of enterobiliary anastomosis. Hepato-gastroenterology 61(135):1867–1870PubMedGoogle Scholar
  15. 15.
    Odisio BC, Richter M, Aloia TA, et al. (2016) Use of prophylactic antibiotics to prevent abscess formation following hepatic ablation in patients with prior enterobiliary manipulation. J Gastrointest Surg 20(8):1428–1434CrossRefGoogle Scholar
  16. 16.
    Welch BT, Callstrom MR, Carpenter PC, et al. (2014) A single-institution experience in image-guided thermal ablation of adrenal gland metastases. J Vasc Interv Radiol 25(4):593–598CrossRefGoogle Scholar
  17. 17.
    Welch BT, Callstrom MR, Morris JM, et al. (2014) Feasibility and oncologic control following percutaneous image-guided ablation of metastatic renal cell carcinoma. J Urol 192:357–363CrossRefGoogle Scholar
  18. 18.
    National Cancer Institute (2009) Common terminology criteria for adverse events (CTCAE) version 4.0. Google Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • B. T. Welch
    • 1
    Email author
  • J. J. Schmitz
    • 1
  • T. D. Atwell
    • 1
  • A. M. McGauvran
    • 1
  • A. N. Kurup
    • 1
  • M. R. Callstrom
    • 1
  • G. D. Schmit
    • 1
  1. 1.Mayo Clinic Department of RadiologyRochesterUSA

Personalised recommendations